Abstract
As residential radon programmes of identification and remediation have proceeded, so questions have been raised about their costs and benefits. This study presents a generalizable model for estimating the cost-effectiveness of a radon mitigation programme using the methodological framework now considered appropriate in the economic evaluation of health interventions. Its use will help to inform future discussion of radon remediation and lung cancer prevention programmes. Data from Northamptonshire were analysed, resulting in a societal cost-effectiveness ratio of £13250 per life-year gained in 1997. The percentage of houses found to be over the action level, and the percentage of householders who decide to remediate are shown to be important parameters for the cost-effectiveness analysis. Questions are raised about the particular importance of perspective in this type of analysis and suggestions are made for future research directions. © 1999 Cancer Research Campaign
Keywords: cost-effectiveness analysis, model, radon remediation, lung cancer, prevention, United Kingdom
Full Text
The Full Text of this article is available as a PDF (70.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Briggs A., Sculpher M., Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994 Mar-Apr;3(2):95–104. doi: 10.1002/hec.4730030206. [DOI] [PubMed] [Google Scholar]
- Darby S., Whitley E., Silcocks P., Thakrar B., Green M., Lomas P., Miles J., Reeves G., Fearn T., Doll R. Risk of lung cancer associated with residential radon exposure in south-west England: a case-control study. Br J Cancer. 1998 Aug;78(3):394–408. doi: 10.1038/bjc.1998.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Denman A. R., Phillips P. S. A review of the cost effectiveness of radon mitigation in domestic properties in Northamptonshire. J Radiol Prot. 1998 Jun;18(2):119–124. doi: 10.1088/0952-4746/18/2/007. [DOI] [PubMed] [Google Scholar]
- Johannesson M., Jönsson B., Kjekshus J., Olsson A. G., Pedersen T. R., Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997 Jan 30;336(5):332–336. doi: 10.1056/NEJM199701303360503. [DOI] [PubMed] [Google Scholar]
- Marcinowski F., Napolitano S. Reducing the risks from radon. Air Waste. 1993 Jul;43(7):955–962. doi: 10.1080/1073161x.1993.10467177. [DOI] [PubMed] [Google Scholar]
- Mossman K. L., Sollitto M. A. Regulatory control of indoor Rn. Health Phys. 1991 Feb;60(2):169–176. doi: 10.1097/00004032-199102000-00004. [DOI] [PubMed] [Google Scholar]
- Phillips P. S., Denman A. R. Radon: a human carcinogen. Sci Prog. 1997;80(Pt 4):317–336. [PubMed] [Google Scholar]
- Wolstenholme J. L., Smith S. J., Whynes D. K. The costs of treating breast cancer in the United Kingdom: implications for screening. Int J Technol Assess Health Care. 1998 Spring;14(2):277–289. doi: 10.1017/s0266462300012253. [DOI] [PubMed] [Google Scholar]